|
Search
Search through the thousands of lawsuits, complaints and recalls on our site.
 |
Case ID: 5018 | Drugs / Medical | 01/23/2008
KGS is investigating lawsuits related to the cholesterol-lowering drugs Zetia (ezetimibe) and Vytorin (a combination of ezetimibe and simvastatin). Zetia was introduced in 2002, and by 2003, it was on the list of top-selling drugs with more than 4.2 million prescriptions written that year. The combination drug Vytorin was introduced one year later, in 2004, but the FDA reviewer of Vytorin recommended against approval of Vytorin. (For excerpts of the recommendation, see www.worstpills.org/public/newsletter.cfm?n_id=353)
On January 15, 2008, the makers of Zetia and Vytorin, Merck and Schering-Plough Pharmaceuticals, released the results of a study that concluded that these drugs are not only ineffective in reducing the chances of heart attack or stroke, but also may actually increase the speed with which artery-clogging plaque may form. The study was completed in April 2006, but Merck and Schering-Plough Pharmaceuticals refused to release the study for 21 months. According to Public Citizen, a National Non-Profit Public Interest Organization, “(t)here is no medical reason for you to be taking Zetia (ezetimibe) or Vytorin (Zetia in combination with simvastatin) when there are safer and more effective drugs, in terms of reducing cardiovascular event, on the market.” www.worstpills.org/public/newsletter.cfm?n_id=353 If you or a loved one has either (1) developed liver toxicity (or any disease associated with liver toxicity such as hepatitis and pancreatitis) after taking Zetia or Vytorin, or (2) paid out of your pocket for either Zetia or Vytorin, click the above link and one of our attorneys will contact you. Register your Schering Plough Merck ComplaintIf you or someone you know has been affected by this case, you may qualify for a money settlement as the result of your financial/economic or other damages that may be awarded either prior to a lawsuit or after the initiation of a lawsuit either currently in progress or filed just for you, possibly a class action lawsuit. Please simply register your complaint by clicking here for Schering Plough Merck, or click the red "submit" button on this page, and a lawyer will review your Schering Plough Merck complaint. By submitting your complaint, you are asking lawyers to contact you. You are under no obligation to accept their services and you are free to choose which lawyer you want to work with. Lawyers are usually paid out of the proceeds of the settlement or verdict rendered - the lawyers work on "contingency" by fronting the costs of your lawsuit based on their belief that they will recover a settlement for you. At Lawcash.com, it is our goal to keep you informed about important legal cases, class actions and settlements. Our lawyers offer free legal evaluations in tort cases, class actions, personal injury, and other lawsuits because we are dedicated to helping you resolve your legal complaints. Other Drugs / Medical Cases of Interest A settlement valued at 65 Million dollars has been reached in the consolidated action concerning alleged efforts by drug manufacturer Smith Kline Beecham to delay or impede the release of generic versions of the antidepressant drug Paxil, in order to continue selling the name brand drug at higher cost. On November 18, 2004 court ordered notification of potential claimainst began. Notices will be mailed, and are scheduled to appear in newspapers and magazines all over the United States, leading up to a hearing on March 9, 2005, when the Court will consider whether to approve the settlement. A class action has been filed against Piedmont Medical Center Hospital in Rock Hill, South Carolina, on behalf of all patients who were treated from January 1, 1997 to the eventual date of any judgment in the action, alleging that the Tenet Healthcare-owned facility overcharged them in violation of its own price gap contract provisions that are designed to keep it from being the most expensive hospital in the vicinity. A class action has been filed against AstraZeneca PLC (NYSE:AZN), a pharmaceutical company and certain of its officers and directors by stockholders who purchased the company's common stock between April 2nd, 2003 and October 11th, 2004. The action claims that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities. The stockholders seek to recover compensatory damages for the loss of value of their stock. Eli Lilly and and the FDA notified healthcare professionals of revisions to the precautions//Hepatotoxicity section of the prescribing information for Cymbalta (duloxetine hydrochloride), indicated for treatment of major depressive disorder and diabetic peripheral neuropathic pain. Women's rights advocates have been pressing ahead in the battle to provide women with parity in the healthcare field. A class action has been filed against Washington state healthcare insurance provider Regence Blue Shield on behalf of female policyholders who allege that they have been denied coverage for FDA-approved forms of contraception, in violation of state insurance and consumer protection laws.
The Tennessee Medical Association and Blue Cross Blue Shield of Tennessee have resolved a five-year class action lawsuit over billing and other business practices. |
IT'S FREE
|
© 2000 - 2008 Copyright. All rights reserved nola3, llc.
